MX428183B - Anticuerpos de quimiocina cxc pan-elr+ para el tratamiento de la hidradenitis supurativa - Google Patents
Anticuerpos de quimiocina cxc pan-elr+ para el tratamiento de la hidradenitis supurativaInfo
- Publication number
- MX428183B MX428183B MX2021004363A MX2021004363A MX428183B MX 428183 B MX428183 B MX 428183B MX 2021004363 A MX2021004363 A MX 2021004363A MX 2021004363 A MX2021004363 A MX 2021004363A MX 428183 B MX428183 B MX 428183B
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- elr
- cxc
- pan
- hidradenitis suppurativa
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
En la presente se proporcionan métodos y usos de anticuerpos contra quimiocinas CXC ELR+ para el tratamiento de la hidradenitis supurativa. También se proporcionan dosis y regímenes de dosis para los métodos y usos de los anticuerpos contra las quimiocinas CXC ELR+ para el tratamiento de la hidradenitis supurativa.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862748838P | 2018-10-22 | 2018-10-22 | |
| US201962791061P | 2019-01-11 | 2019-01-11 | |
| PCT/US2019/056250 WO2020086327A1 (en) | 2018-10-22 | 2019-10-15 | Pan-elr+ cxc chemokine antibodies for the treatment of hidradenitis suppurativa |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2021004363A MX2021004363A (es) | 2021-05-31 |
| MX428183B true MX428183B (es) | 2025-11-13 |
Family
ID=68425364
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021004363A MX428183B (es) | 2018-10-22 | 2019-10-15 | Anticuerpos de quimiocina cxc pan-elr+ para el tratamiento de la hidradenitis supurativa |
| MX2025011694A MX2025011694A (es) | 2018-10-22 | 2021-04-15 | Anticuerpos de quimiocina cxc pan-elr+ para el tratamiento de la hidradenitis supurativa |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025011694A MX2025011694A (es) | 2018-10-22 | 2021-04-15 | Anticuerpos de quimiocina cxc pan-elr+ para el tratamiento de la hidradenitis supurativa |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US12037387B2 (es) |
| EP (2) | EP3870288B1 (es) |
| JP (2) | JP7171913B2 (es) |
| KR (3) | KR20240014601A (es) |
| CN (2) | CN118846041A (es) |
| AU (1) | AU2019364239B2 (es) |
| BR (2) | BR122023023399A2 (es) |
| DK (1) | DK3870288T3 (es) |
| ES (1) | ES3009417T3 (es) |
| FI (1) | FI3870288T3 (es) |
| HR (1) | HRP20250145T1 (es) |
| HU (1) | HUE070192T2 (es) |
| IL (2) | IL282307B2 (es) |
| LT (1) | LT3870288T (es) |
| MA (1) | MA53976B1 (es) |
| MD (1) | MD3870288T2 (es) |
| MX (2) | MX428183B (es) |
| MY (1) | MY197879A (es) |
| NZ (1) | NZ775058A (es) |
| PL (1) | PL3870288T3 (es) |
| PT (1) | PT3870288T (es) |
| RS (1) | RS66419B1 (es) |
| SG (1) | SG11202102904TA (es) |
| SI (1) | SI3870288T1 (es) |
| TW (1) | TWI737000B (es) |
| UA (1) | UA128649C2 (es) |
| WO (1) | WO2020086327A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202206457A (zh) * | 2020-04-24 | 2022-02-16 | 美商美國禮來大藥廠 | 用於治療呼吸疾病之泛elr+ cxc趨化因子抗體 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2012014080A (es) * | 2010-06-03 | 2013-05-01 | Abbvie Biotechnology Ltd | Usos y composiciones para el tratamiento de hidradenitis superativa (hs). |
| TWI612059B (zh) * | 2013-03-15 | 2018-01-21 | 美國禮來大藥廠 | 泛－ＥＬＲ<sup>＋</sup>ＣＸＣ趨化因子抗體 |
| US9290570B2 (en) * | 2013-03-15 | 2016-03-22 | Eli Lilly And Company | Pan-ELR+ CXC Chemokine Antibodies |
| KR101418306B1 (ko) | 2013-03-19 | 2014-07-15 | 김대운 | 바지의 흘러내림 방지용 버팀기둥 |
| WO2015197098A1 (en) * | 2014-06-26 | 2015-12-30 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
| EP3234135B1 (en) * | 2014-12-18 | 2020-04-29 | Csir | Immunomodulation by controlling elr+ proinflammatory chemokine levels with the long non-coding rna umlilo |
| JP7145162B2 (ja) * | 2017-02-16 | 2022-09-30 | ヤンセン バイオテク，インコーポレイテッド | 化膿性汗腺炎の処置 |
-
2019
- 2019-10-08 TW TW108136327A patent/TWI737000B/zh active
- 2019-10-15 BR BR122023023399-9A patent/BR122023023399A2/pt unknown
- 2019-10-15 CN CN202411069386.1A patent/CN118846041A/zh active Pending
- 2019-10-15 SI SI201930876T patent/SI3870288T1/sl unknown
- 2019-10-15 IL IL282307A patent/IL282307B2/en unknown
- 2019-10-15 EP EP19797521.2A patent/EP3870288B1/en active Active
- 2019-10-15 MX MX2021004363A patent/MX428183B/es unknown
- 2019-10-15 JP JP2021521030A patent/JP7171913B2/ja active Active
- 2019-10-15 UA UAA202101781A patent/UA128649C2/uk unknown
- 2019-10-15 KR KR1020247002081A patent/KR20240014601A/ko not_active Ceased
- 2019-10-15 BR BR112021004900-2A patent/BR112021004900A2/pt unknown
- 2019-10-15 HU HUE19797521A patent/HUE070192T2/hu unknown
- 2019-10-15 RS RS20250038A patent/RS66419B1/sr unknown
- 2019-10-15 LT LTEPPCT/US2019/056250T patent/LT3870288T/lt unknown
- 2019-10-15 HR HRP20250145TT patent/HRP20250145T1/hr unknown
- 2019-10-15 US US17/284,611 patent/US12037387B2/en active Active
- 2019-10-15 MY MYPI2021002149A patent/MY197879A/en unknown
- 2019-10-15 NZ NZ775058A patent/NZ775058A/en unknown
- 2019-10-15 EP EP24217370.6A patent/EP4545560A3/en active Pending
- 2019-10-15 MD MDE20210821T patent/MD3870288T2/ro unknown
- 2019-10-15 PT PT197975212T patent/PT3870288T/pt unknown
- 2019-10-15 AU AU2019364239A patent/AU2019364239B2/en active Active
- 2019-10-15 FI FIEP19797521.2T patent/FI3870288T3/fi active
- 2019-10-15 KR KR1020217011560A patent/KR102628314B1/ko active Active
- 2019-10-15 SG SG11202102904TA patent/SG11202102904TA/en unknown
- 2019-10-15 PL PL19797521.2T patent/PL3870288T3/pl unknown
- 2019-10-15 MA MA53976A patent/MA53976B1/fr unknown
- 2019-10-15 DK DK19797521.2T patent/DK3870288T3/da active
- 2019-10-15 ES ES19797521T patent/ES3009417T3/es active Active
- 2019-10-15 CN CN201980069911.0A patent/CN112912140B/zh active Active
- 2019-10-15 WO PCT/US2019/056250 patent/WO2020086327A1/en not_active Ceased
- 2019-10-15 KR KR1020257005931A patent/KR20250029297A/ko active Pending
-
2021
- 2021-04-15 MX MX2025011694A patent/MX2025011694A/es unknown
-
2022
- 2022-11-02 JP JP2022176098A patent/JP7410256B2/ja active Active
-
2024
- 2024-06-05 US US18/734,020 patent/US20240425577A1/en active Pending
-
2025
- 2025-10-19 IL IL324054A patent/IL324054A/en unknown